[
  {
    "ts": null,
    "headline": "Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago.",
    "url": "https://finnhub.io/api/news?id=388f692ecbd51c9b58bb775f1835af29b25ba531bba58ebc1b2460e5da633dbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748552400,
      "headline": "Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions",
      "id": 134870606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions taking place June 20-23 in Chicago.",
      "url": "https://finnhub.io/api/news?id=388f692ecbd51c9b58bb775f1835af29b25ba531bba58ebc1b2460e5da633dbd"
    }
  },
  {
    "ts": null,
    "headline": "Was Jim Cramer Right About Eli Lilly and Company (LLY)?",
    "summary": "We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. In that episode, a caller asked about Eli Lilly and Company (NYSE:LLY), particularly in […]",
    "url": "https://finnhub.io/api/news?id=d8e1eef71d3b3bda6a1df36bfaf431444574d14c045b187f616333447bc111df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748551428,
      "headline": "Was Jim Cramer Right About Eli Lilly and Company (LLY)?",
      "id": 134856538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. In that episode, a caller asked about Eli Lilly and Company (NYSE:LLY), particularly in […]",
      "url": "https://finnhub.io/api/news?id=d8e1eef71d3b3bda6a1df36bfaf431444574d14c045b187f616333447bc111df"
    }
  },
  {
    "ts": null,
    "headline": "PFE or LLY: Which Is the Better Value Stock Right Now?",
    "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=b7e79bd5aba226b382378eba551109b75588fbe4c911bf671ecbd6e15170cd44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748533208,
      "headline": "PFE or LLY: Which Is the Better Value Stock Right Now?",
      "id": 134844496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "PFE vs. LLY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=b7e79bd5aba226b382378eba551109b75588fbe4c911bf671ecbd6e15170cd44"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Labelling Changes For Trulicity, Saxenda & Xultophy 100/3.6 To Include 'Alopecia' & 'Dysesthesia'",
    "summary": "US FDA: * US FDA APPROVES LABELLING CHANGES FOR TRULICITY, SAXENDA &XULTOPHY 100/3.6 TO INCLUDE ‘ALOPECIA’ & ‘DYSESTHESIA’ INLETTERS DATED MAY 28 - WEBSITE * US...",
    "url": "https://finnhub.io/api/news?id=79d7541c0f76347d5a6feeaca74820898845b99b3d449450530e27e94847e0f6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748530328,
      "headline": "FDA Approves Labelling Changes For Trulicity, Saxenda & Xultophy 100/3.6 To Include 'Alopecia' & 'Dysesthesia'",
      "id": 134840257,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "US FDA: * US FDA APPROVES LABELLING CHANGES FOR TRULICITY, SAXENDA &XULTOPHY 100/3.6 TO INCLUDE ‘ALOPECIA’ & ‘DYSESTHESIA’ INLETTERS DATED MAY 28 - WEBSITE * US...",
      "url": "https://finnhub.io/api/news?id=79d7541c0f76347d5a6feeaca74820898845b99b3d449450530e27e94847e0f6"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly",
    "summary": "Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.",
    "url": "https://finnhub.io/api/news?id=c0f5feaa5b36eab257ca0941b6e4bc12ecc7c88b138fd770b92063c8577bd5f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748528872,
      "headline": "Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly",
      "id": 134811781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.",
      "url": "https://finnhub.io/api/news?id=c0f5feaa5b36eab257ca0941b6e4bc12ecc7c88b138fd770b92063c8577bd5f3"
    }
  },
  {
    "ts": null,
    "headline": "Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.",
    "summary": "Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.",
    "url": "https://finnhub.io/api/news?id=f272a3cef6c1df46d6329ad9d7ad6e60f6ca021b1a417de3d2151a63ce6949b0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748527740,
      "headline": "Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.",
      "id": 134895320,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.",
      "url": "https://finnhub.io/api/news?id=f272a3cef6c1df46d6329ad9d7ad6e60f6ca021b1a417de3d2151a63ce6949b0"
    }
  },
  {
    "ts": null,
    "headline": "How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created",
    "summary": "Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the company is trying to get back on track.",
    "url": "https://finnhub.io/api/news?id=8eb943f30e48d58a5bce15cb4db10d5e3ae414d3e1e2f923cef3d4a378cd7ff4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748480400,
      "headline": "How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created",
      "id": 134790389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the company is trying to get back on track.",
      "url": "https://finnhub.io/api/news?id=8eb943f30e48d58a5bce15cb4db10d5e3ae414d3e1e2f923cef3d4a378cd7ff4"
    }
  }
]